electED.

HR 8857 · 119th Congress — Next GEN Act of 2026

This bill would amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program. Right now, the latest action is: Sent to the…

Congress
119
Bill
HR 8857
Status
Introduced
Introduced
2026-05-15
Latest action date
2026-05-15

Summary

This bill would amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program. Right now, the latest action is: Sent to the Energy and Commerce Committee and the Ways and Means Committee. Each committee will review the parts it handles. The listed sponsor is Rep. Morelle, Joseph D. [D-NY-25] [D].

This summary may describe an earlier version. Check the official record for current wording.

Latest action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsors

Sources